Inspyr Therapeutics, Inc. Stock Other OTC
Equities
NSPX
US45782A4031
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 241K |
---|---|---|---|---|---|
Net income 2021 | 2M | Net income 2022 | -1M | EV / Sales 2021 | - |
Net cash position 2021 | 197K | Net Debt 2022 | 305K | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.4
x | P/E ratio 2022 |
-0.23
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 08-01-31 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 16-10-11 |
1st Jan change | Capi. | |
---|---|---|
+16.13% | 122B | |
+19.65% | 115B | |
+21.22% | 26.64B | |
-23.84% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-19.28% | 15.49B | |
+63.81% | 14.83B | |
+1.94% | 13.67B |